Nafazatrom

Overview

Nafazatrom (Bay g 6575) is an orally active cardioprotective agent that protects against ischemic damage. Nafazatrom dose-dependently inhibits neutrophil aggregation, superoxide anion generation, arachidonic acid metabolism, and to a lesser extent the release of β-glucosidase, platelet aggregation or arachidonic acid in vitro. Acid metabolism has no significant effect. In a dog ischemia-reperfusion model, Nafazatrom (10 mg/kg; po) reduced infarct size and the occurrence of arrhythmias and rescued ischemic myocardial function without affecting any hemodynamic changes. The basis of Nafazatrom's cardioprotection may be inhibition of neutrophil function and cellular infiltration in vitro.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Lipoxygenase

Product Information

• Catalog No.: HY-121586
• CAS No.: 59040-30-1
• Molecular Formula: C16H16N2O2
• Molecular Weight: 268.31
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source